T6336

Amonafide (NSC-308847,AS1413)(AS1413) produces protein-associated DNA-strand breaks through a topoisomerase II-mediated reaction, but does not produce topoisomerase I-mediated DNA cleavage.

DNA topoisomerase II inhibitor 1 is a potent inhibitor of DNA topoisomerase II that arrests the cell cycle in sub-G1 phase and induces apoptosis with anti-value-added effects.

α-Glucosidase-IN-13 is an inhibitor of α-glucosidase (IC50: 5.69 μM).

Ulecaciclib is an orally active, blood-brain barrier-transparent, cell cycle protein-dependent kinase (CDK) inhibitor that exhibits favorable pharmacokinetic profiles, with ki of 0.62 μM (CDK2/Cyclin A), 3 nM (CDK6/Cyclin D3), 0.2 nM (CDK4/Cyclin D1) and 0.63 μM (CDK7/Cyclin H) for CDKs. D1) and 0.63 μM (CDK7/Cyclin H).

HIV-1 inhibitor-19 is a potent inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRTI) that targets L100I, K103N, and V106A/F227L mutant strains with EC50s of 7.3 nM, 9.2 nM, and 21.0 nM, respectively.

Nrf2 activator-5 is a potent activator of Nrf2 that attenuates H2O2-induced oxidative stress and LPS-stimulated inflammation in BV-2 microglia, exhibiting antioxidant and anti-inflammatory activity.

RAF-IN-1 is a potent inhibitor of b/cRAF, acting on cRAF (IC50: 3.8 nM), bRAFwt (IC50: 36 nM), bRAFV600E (IC50: 29.4 nM) and inhibiting A375 and H358 cell lines carrying the bRAFV600E mutation with a GI50 of 3.4 and 2.9 nM.

Anticancer agent 31 is an anticancer agent, a 1,3-diphenylurea quinoxaline derivative. anticancer agent 31 exhibits antitumor effects by blocking the cell cycle in S phase and inducing apoptosis.

CDK7-IN-2 is a potent inhibitor of CDK7, which plays a role in transcription initiation via phosphorylation of the Rbpl subunit of RNA polymerase II (RNAPII). CDK7 is linked to the temporal control of the cell cycle and transcriptional activity, and has research potential for aggressive and difficult-to-treat cancers.

CXCR4 antagonist 4 is an orally active and potent CXCR4 antagonist with an IC50 of 24 nM. CXCR4 antagonist 4 inhibits CYP 2D6 activity, increases PAMPA permeability, and effectively blocks entry of human immunodeficiency virus (IC50=7 nM).